Marburg Virus Vaccine Safety Trial
Part of Infections clinical trials.
This trial tests a new vaccine to protect against Marburg virus, a rare but serious infection. The vaccine uses a weakened virus to teach your body to fight the Marburg virus, and researchers are checking if it is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old and in good general health.
- You are willing to use condoms or effective birth control for 3 months after getting the vaccine.
- You agree to get HIV testing and counseling as part of the study.
- You have not been exposed to Marburg virus or received a Marburg/Ebola vaccine before.
- You do not have a weakened immune system, autoimmune disease, or take immune-suppressing medications.
- You are not pregnant or breastfeeding, and you do not have a bleeding disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental vaccine designed to protect against Sudan virus, a rare but serious disease. Researchers will check if the vaccine is safe and helps your immune system fight off the virus.
This study tests how safe a Rift Valley fever (RVF) vaccine is and how strongly it triggers the body’s immune response. You may be eligible if you are at risk of RVF exposure and your blood test shows you don’t already have strong protection.
This Phase 1/2 study tests a new vaccine meant to protect young children against malaria. If you qualify, your baby would get the study vaccine and be followed for about 12 months to check safety and early signs of protection.
This trial tests a new rabies vaccine to see how well it works and if it is safe for people who have not been exposed to rabies. It may be a good option if you want protection before potential exposure.
This study tests a new RSV vaccine to see if it is safe for healthy adults. It uses mRNA technology to help your body build protection against RSV, a common respiratory virus.
This study tests a new vaccine that targets two respiratory viruses, RSV and HMPV, to see if it's safe and effective in adults 60 years and older. It may help prevent serious lung infections caused by these viruses.
Hear when a new Marburg Virus Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.